US6534261B1
(en)
|
1999-01-12 |
2003-03-18 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
US20020064802A1
(en)
|
2000-04-28 |
2002-05-30 |
Eva Raschke |
Methods for binding an exogenous molecule to cellular chromatin
|
US20050136040A1
(en)
|
2001-10-11 |
2005-06-23 |
Imperial College Innovations Limited |
Control of gene expression using a complex of an oligonucleotide and a regulatory peptide
|
GB0124391D0
(en)
|
2001-10-11 |
2001-11-28 |
Gene Expression Technologies L |
Control of gene expression
|
WO2003080809A2
(en)
|
2002-03-21 |
2003-10-02 |
Sangamo Biosciences, Inc. |
Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
|
ITMI20030821A1
(it)
|
2003-04-18 |
2004-10-19 |
Internat Ct For Genetic En Gineering And |
Polipeptidi chimerici e loro uso.
|
CN1836048A
(zh)
|
2003-06-10 |
2006-09-20 |
图尔金株式会社 |
可转导的dna结合蛋白
|
US8133733B2
(en)
|
2003-10-24 |
2012-03-13 |
Gencia Corporation |
Nonviral vectors for delivering polynucleotides to target tissues
|
US20070254291A1
(en)
|
2004-06-14 |
2007-11-01 |
Xiaoxia Cui |
Gene Targeting in Eukaryotic Cells by Group II Intron Ribonucleoprotein Particles
|
US10022457B2
(en)
|
2005-08-05 |
2018-07-17 |
Gholam A. Peyman |
Methods to regulate polarization and enhance function of cells
|
EP3284833B1
(en)
|
2005-08-26 |
2021-12-01 |
DuPont Nutrition Biosciences ApS |
Use of crispr associated genes (cas)
|
CA2660485C
(en)
|
2006-08-11 |
2016-04-12 |
Sangamo Biosciences, Inc. |
Zinc finger nuclease-mediated homologous recombination
|
US20110239315A1
(en)
|
2009-01-12 |
2011-09-29 |
Ulla Bonas |
Modular dna-binding domains and methods of use
|
WO2010129023A2
(en)
|
2009-04-28 |
2010-11-11 |
President And Fellows Of Harvard College |
Supercharged proteins for cell penetration
|
WO2011059836A2
(en)
|
2009-10-29 |
2011-05-19 |
Trustees Of Dartmouth College |
T cell receptor-deficient t cell compositions
|
US8956828B2
(en)
|
2009-11-10 |
2015-02-17 |
Sangamo Biosciences, Inc. |
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
|
CN106834320B
(zh)
|
2009-12-10 |
2021-05-25 |
明尼苏达大学董事会 |
Tal效应子介导的dna修饰
|
US9567573B2
(en)
|
2010-04-26 |
2017-02-14 |
Sangamo Biosciences, Inc. |
Genome editing of a Rosa locus using nucleases
|
US8876458B2
(en)
|
2011-01-25 |
2014-11-04 |
United Technologies Corporation |
Blade outer air seal assembly and support
|
WO2013074916A1
(en)
|
2011-11-18 |
2013-05-23 |
Board Of Regents, The University Of Texas System |
Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
|
GB201122458D0
(en)
|
2011-12-30 |
2012-02-08 |
Univ Wageningen |
Modified cascade ribonucleoproteins and uses thereof
|
US20130236504A1
(en)
|
2012-03-06 |
2013-09-12 |
Medical University Of South Carolina |
Delivery System for Enhancing Drug Efficacy
|
UA118014C2
(uk)
|
2012-05-25 |
2018-11-12 |
Те Ріджентс Оф Те Юніверсіті Оф Каліфорнія |
Спосіб модифікації днк-мішені
|
CN110669746B
(zh)
|
2012-10-23 |
2024-04-16 |
基因工具股份有限公司 |
用于切割靶dna的组合物及其用途
|
IL300199A
(en)
|
2012-12-06 |
2023-03-01 |
Sigma Aldrich Co Llc |
CRISPR-based genome modification and regulation
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
EP2931899A1
(en)
|
2012-12-12 |
2015-10-21 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
|
CA2894668A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Crispr-cas systems and methods for altering expression of gene products in eukaryotic cells
|
ES2741951T3
(es)
|
2012-12-17 |
2020-02-12 |
Harvard College |
Modificación por ingeniería genética del genoma humano guiada por ARN
|
KR20140101203A
(ko)
|
2013-02-08 |
2014-08-19 |
이정민 |
자동 버핑장치
|
CA3161835A1
(en)
|
2013-03-15 |
2014-09-25 |
The General Hospital Corporation |
Rna-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
|
WO2014153470A2
(en)
|
2013-03-21 |
2014-09-25 |
Sangamo Biosciences, Inc. |
Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases
|
EP2981614A1
(en)
|
2013-04-02 |
2016-02-10 |
Bayer CropScience NV |
Targeted genome engineering in eukaryotes
|
ES2883131T3
(es)
|
2013-05-29 |
2021-12-07 |
Cellectis |
Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN
|
DK3309248T3
(da)
|
2013-05-29 |
2021-08-02 |
Cellectis |
Fremgangsmåde til manipulering af T-celler til immunterapi under anvendelse af et RNA-guidet CAS-nuklease-system
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
WO2015048690A1
(en)
|
2013-09-27 |
2015-04-02 |
The Regents Of The University Of California |
Optimized small guide rnas and methods of use
|
CN110713995B
(zh)
|
2013-10-17 |
2023-08-01 |
桑格摩生物科学股份有限公司 |
用于核酸酶介导的基因组工程改造的递送方法和组合物
|
US9951353B2
(en)
|
2013-11-15 |
2018-04-24 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Engineering neural stem cells using homologous recombination
|
US10787684B2
(en)
*
|
2013-11-19 |
2020-09-29 |
President And Fellows Of Harvard College |
Large gene excision and insertion
|
CA2932436A1
(en)
*
|
2013-12-12 |
2015-06-18 |
The Broad Institute, Inc. |
Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders
|
KR20160089526A
(ko)
|
2013-12-12 |
2016-07-27 |
더 브로드 인스티튜트, 인코퍼레이티드 |
입자 전달 성분을 이용한 표적 장애 및 질병에 대한 crispr-cas 시스템 및 조성물의 전달, 이용 및 치료 적용
|
JP6793547B2
(ja)
|
2013-12-12 |
2020-12-02 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
最適化機能CRISPR−Cas系による配列操作のための系、方法および組成物
|
SG10201804976YA
(en)
|
2013-12-12 |
2018-07-30 |
Broad Inst Inc |
Delivery, Use and Therapeutic Applications of the Crispr-Cas Systems and Compositions for Genome Editing
|
US20160304893A1
(en)
|
2013-12-13 |
2016-10-20 |
Cellectis |
Cas9 nuclease platform for microalgae genome engineering
|
KR102415811B1
(ko)
|
2014-01-31 |
2022-07-04 |
팩터 바이오사이언스 인크. |
핵산 제조 및 송달을 위한 방법 및 산물
|
WO2015115903A1
(en)
|
2014-02-03 |
2015-08-06 |
Academisch Ziekenhuis Leiden H.O.D.N. Lumc |
Site-specific dna break-induced genome editing using engineered nucleases
|
KR20230152175A
(ko)
|
2014-04-18 |
2023-11-02 |
에디타스 메디신, 인코포레이티드 |
암 면역요법을 위한 crispr-cas-관련 방법, 조성물 및 구성성분
|
JP6598860B2
(ja)
|
2014-08-06 |
2019-10-30 |
カレッジ オブ メディシン ポチョン チャ ユニバーシティ インダストリー−アカデミック コーオペレイション ファウンデーション |
Hlaをコードする遺伝子のヌクレアーゼ媒介編集により作製される免疫適合性細胞
|
US10570418B2
(en)
|
2014-09-02 |
2020-02-25 |
The Regents Of The University Of California |
Methods and compositions for RNA-directed target DNA modification
|
WO2016049251A1
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes
|
EP3998344A1
(en)
|
2014-10-09 |
2022-05-18 |
Life Technologies Corporation |
Crispr oligonucleotides and gene editing
|
CA2964953A1
(en)
|
2014-10-31 |
2016-05-06 |
The Trustees Of The University Of Pennsylvania |
Altering gene expression in cart cells and uses thereof
|
WO2016097751A1
(en)
|
2014-12-18 |
2016-06-23 |
The University Of Bath |
Method of cas9 mediated genome engineering
|
WO2016118697A1
(en)
|
2015-01-21 |
2016-07-28 |
Phaserx, Inc. |
Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells
|
EP3250693B2
(en)
|
2015-01-30 |
2023-12-20 |
The Regents of The University of California |
Protein delivery in primary hematopoietic cells
|
US20180200387A1
(en)
|
2015-02-23 |
2018-07-19 |
Crispr Therapeutics Ag |
Materials and methods for treatment of human genetic diseases including hemoglobinopathies
|
US20180298340A1
(en)
|
2015-04-24 |
2018-10-18 |
The Regents Of The University Of California |
Systems for detecting, monitoring or treating diseases or conditions using engineered cells and methods for making and using them
|
EP3303586A1
(en)
|
2015-05-29 |
2018-04-11 |
Juno Therapeutics, Inc. |
Composition and methods for regulating inhibitory interactions in genetically engineered cells
|
WO2016205703A1
(en)
|
2015-06-17 |
2016-12-22 |
The Uab Research Foundation |
Crispr/cas9 complex for genomic editing
|
JP2018518181A
(ja)
|
2015-06-17 |
2018-07-12 |
ザ ユーエービー リサーチ ファンデーション |
血液細胞系列の細胞に機能的ポリペプチドを導入するためのCRISPR/Cas9複合体
|
US20170000743A1
(en)
|
2015-07-02 |
2017-01-05 |
Vindico NanoBio Technology Inc. |
Compositions and Methods for Delivery of Gene Editing Tools Using Polymeric Vesicles
|
CA2991301A1
(en)
|
2015-07-13 |
2017-01-19 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
US9512446B1
(en)
|
2015-08-28 |
2016-12-06 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
US20180243446A1
(en)
|
2015-09-01 |
2018-08-30 |
The Hospital For Sick Children |
Method and compositions for removing duplicated copy number variaions (cnvs) for genetic disorders and related uses
|
WO2017053729A1
(en)
|
2015-09-25 |
2017-03-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Nuclease-mediated genome editing of primary cells and enrichment thereof
|
US11286480B2
(en)
|
2015-09-28 |
2022-03-29 |
North Carolina State University |
Methods and compositions for sequence specific antimicrobials
|
DK3359184T3
(da)
|
2015-10-05 |
2020-06-15 |
Prec Biosciences Inc |
Genetisk modificerede celler, der omfatter et modificeret gen fra konstant alfaregion i human t-cellereceptor
|
EP3365269A4
(en)
|
2015-10-19 |
2019-06-19 |
The Methodist Hospital |
DISTRIBUTION, BY MEMBRANE DEFORMATION, FROM CRISPR-CAS9 TO DIFFICULT CELLS TO BE TRANSFERRED
|
EP3365454A1
(en)
|
2015-10-20 |
2018-08-29 |
10X Genomics, Inc. |
Methods and systems for high throughput single cell genetic manipulation
|
WO2017070429A1
(en)
|
2015-10-22 |
2017-04-27 |
Regents Of The University Of Minnesota |
Methods involving editing polynucleotides that encode t cell receptor
|
WO2017079673A1
(en)
|
2015-11-04 |
2017-05-11 |
Fate Therapeutics, Inc. |
Genomic engineering of pluripotent cells
|
WO2017091630A1
(en)
|
2015-11-23 |
2017-06-01 |
The Regents Of The University Of California |
Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9
|
BR112018011089A2
(pt)
*
|
2015-12-04 |
2018-12-04 |
Intellia Therapeutics Inc |
composições e métodos para a imuno-oncologia
|
CA3008413A1
(en)
|
2015-12-18 |
2017-06-22 |
Sangamo Therapeutics, Inc. |
Targeted disruption of the t cell receptor
|
EP3397760A2
(en)
|
2015-12-30 |
2018-11-07 |
Avectas Limited |
Vector-free delivery of gene editing proteins and compositions to cells and tissues
|
KR102386029B1
(ko)
|
2016-03-11 |
2022-04-13 |
2세븐티 바이오, 인코포레이티드 |
게놈 편집 면역 효과기 세포
|
AU2017248259A1
(en)
|
2016-04-07 |
2018-10-25 |
Bluebird Bio, Inc. |
Chimeric antigen receptor T cell compositions
|
CA3020857A1
(en)
|
2016-04-14 |
2017-10-19 |
Fred Hutchinson Cancer Research Center |
Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
|
US10188749B2
(en)
|
2016-04-14 |
2019-01-29 |
Fred Hutchinson Cancer Research Center |
Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
|
ES2933961T3
(es)
|
2016-04-15 |
2023-02-15 |
Memorial Sloan Kettering Cancer Center |
Células T transgénicas y composiciones de células T de receptor de antígeno quimérico y métodos relacionados
|
EP3448995A1
(en)
*
|
2016-04-25 |
2019-03-06 |
Universität Basel |
Allele editing and applications thereof
|
WO2017189336A1
(en)
|
2016-04-25 |
2017-11-02 |
The Regents Of The University Of California |
Methods and compositions for genomic editing
|
JP7184648B2
(ja)
|
2016-04-29 |
2022-12-06 |
ビーエーエスエフ プラント サイエンス カンパニー ゲーエムベーハー |
標的核酸の改変のための改善された方法
|
US20190136224A1
(en)
|
2016-05-31 |
2019-05-09 |
Massachusetts Institute Of Technology |
Hydrodynamically Controlled Electric Fields for High Throughput Transformation & High Throughput Parallel Transformation Platform
|
EP3472338B1
(en)
|
2016-06-20 |
2024-05-22 |
Octapharma AG |
Means and methods for modifying multiple alleles
|
WO2018035387A1
(en)
|
2016-08-17 |
2018-02-22 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
US11999931B2
(en)
|
2016-08-20 |
2024-06-04 |
The Regents Of The University Of California |
High-throughput system and method for the temporary permeabilization of cells
|
EP3526235A4
(en)
|
2016-10-12 |
2021-03-10 |
Feldan Bio Inc. |
RATIONALLY DESIGNED SYNTHETIC PEPTIDE SHUTTLE ACTIVE INGREDIENTS FOR ADMINISTRATION OF POLYPEPTIDE FREIGHT FROM AN EXTRACELLULAR ROOM TO THE CYTOSOL AND / OR THE CORE OF AN EUCARYOTIC TARGET CELL, USES TOGETHER THEREFORE, AND KITS IN THE PROCEDURE
|
WO2018073391A1
(en)
|
2016-10-19 |
2018-04-26 |
Cellectis |
Targeted gene insertion for improved immune cells therapy
|
WO2018073393A2
(en)
|
2016-10-19 |
2018-04-26 |
Cellectis |
Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
|
WO2018094291A1
(en)
|
2016-11-18 |
2018-05-24 |
Christopher Bradley |
Massively multiplexed homologous template repair for whole-genome replacement
|
WO2018112282A1
(en)
|
2016-12-14 |
2018-06-21 |
Ligandal, Inc. |
Compositions and methods for nucleic acid and/or protein payload delivery
|
EP3562594A4
(en)
|
2016-12-30 |
2020-09-09 |
The Regents of University of California |
PROCESSES FOR SELECTING AND GENERATING T-LYMPHOCYTES MODIFIED BY THE GENOME
|
CA3080415A1
(en)
|
2017-10-27 |
2019-05-02 |
The Regents Of The University Of California |
Targeted replacement of endogenous t cell receptors
|
JP7397791B2
(ja)
|
2017-10-30 |
2023-12-13 |
パクト ファーマ インコーポレイテッド |
初代細胞の遺伝子編集
|